Search details
1.
Joint ESPGHAN/NASPGHAN Guidelines on Childhood Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic Esophagitis.
J Pediatr Gastroenterol Nutr
; 78(1): 122-152, 2024 01.
Article
in English
| MEDLINE | ID: mdl-38291684
2.
Transcultural adaptation to Spain of the CDPQOL questionnaire specific for coeliac children.
Eur J Pediatr
; 2024 May 03.
Article
in English
| MEDLINE | ID: mdl-38700691
3.
Determinant factors for first-line treatment choice and effectiveness in pediatric eosinophilic esophagitis: an analysis of the EUREOS EoE CONNECT registry.
Eur J Pediatr
; 2024 May 31.
Article
in English
| MEDLINE | ID: mdl-38819501
4.
Proton Pump Inhibitor Therapy in Pediatric Eosinophilic Esophagitis: Predictive Factors and Long-Term Step-Down Efficacy.
J Pediatr Gastroenterol Nutr
; 76(2): 191-198, 2023 02 01.
Article
in English
| MEDLINE | ID: mdl-36416845
5.
Joint ESPGHAN/NASPGHAN Guidelines on Childhood Eosinophilic Gastrointestinal Disorders beyond Eosinophilic Esophagitis.
J Pediatr Gastroenterol Nutr
; 2023 Jul 04.
Article
in English
| MEDLINE | ID: mdl-37399187
6.
Medical treatment of eosinophilic esophagitis.
Cochrane Database Syst Rev
; 7: CD004065, 2023 07 20.
Article
in English
| MEDLINE | ID: mdl-37470293
7.
International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature.
Clin Gastroenterol Hepatol
; 20(11): 2474-2484.e3, 2022 11.
Article
in English
| MEDLINE | ID: mdl-35181570
8.
STAT6 Variants Associate With Relapse of Eosinophilic Esophagitis in Patients Receiving Long-term Proton Pump Inhibitor Therapy.
Clin Gastroenterol Hepatol
; 19(10): 2046-2053.e2, 2021 10.
Article
in English
| MEDLINE | ID: mdl-32798708
9.
Rising trend in pâediatric eosinophilic esophagitis incidence in Spain: Results of a prospective study 2014-16.
Pediatr Allergy Immunol
; 32(6): 1307-1315, 2021 08.
Article
in English
| MEDLINE | ID: mdl-33934414
10.
Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
Eur J Pediatr
; 180(9): 3029-3038, 2021 Sep.
Article
in English
| MEDLINE | ID: mdl-33880650
11.
Management of small intestinal bacterial overgrowth by pediatric gastroenterologists in Spain.
Rev Esp Enferm Dig
; 113(6): 436-441, 2021 Jun.
Article
in English
| MEDLINE | ID: mdl-33371710
12.
Sustained Remission of Eosinophilic Esophagitis Following Discontinuation of Dietary Elimination in Children.
Clin Gastroenterol Hepatol
; 18(1): 249-251.e1, 2020 01.
Article
in English
| MEDLINE | ID: mdl-30880275
13.
Dietary treatment of eosinophilic gastrointestinal disorders in children.
Curr Opin Clin Nutr Metab Care
; 23(3): 210-216, 2020 05.
Article
in English
| MEDLINE | ID: mdl-32068545
14.
Proton-pump Inhibitor Response Prediction Using Esophageal microRNAs in Children With Eosinophilic Esophagitis.
J Pediatr Gastroenterol Nutr
; 71(6): 755-763, 2020 12.
Article
in English
| MEDLINE | ID: mdl-33003164
15.
Differences in Management of Eosinophilic Esophagitis in Europe: An Assessment of Current Practice.
J Pediatr Gastroenterol Nutr
; 71(1): 83-90, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32097371
16.
CYP2C19 and STAT6 Variants Influence the Outcome of Proton Pump Inhibitor Therapy in Pediatric Eosinophilic Esophagitis.
J Pediatr Gastroenterol Nutr
; 69(5): 581-587, 2019 11.
Article
in English
| MEDLINE | ID: mdl-31490856
17.
Helicobacter pylori infection does not protect against eosinophilic esophagitis: results from a large multicenter case-control study.
Am J Gastroenterol
; 113(7): 972-979, 2018 07.
Article
in English
| MEDLINE | ID: mdl-29545632
18.
Long-term Treatment With Proton Pump Inhibitors Is Effective in Children With Eosinophilic Esophagitis.
J Pediatr Gastroenterol Nutr
; 67(2): 210-216, 2018 08.
Article
in English
| MEDLINE | ID: mdl-29509636
19.
High Prevalence of Response to Proton-pump Inhibitor Treatment in Children With Esophageal Eosinophilia.
J Pediatr Gastroenterol Nutr
; 62(5): 704-10, 2016 05.
Article
in English
| MEDLINE | ID: mdl-26513622
20.
Correction to: Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicenter Spanish study.
Eur J Pediatr
; 180(9): 3039-3040, 2021 Sep.
Article
in English
| MEDLINE | ID: mdl-34027626